Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417742 | 1.00 | KIF11 (0.51) | KIF11ALDH1A3NOTUMALDH1A1ALDH3A1 | |
| SCHEMBL14593109 | 0.85 | ALDH1A3 (0.41) | KIF11ALDH1A3NOTUMALDH1A1ALDH3A1 | |
| SCHEMBL5546389 | 0.84 | KIF11 (0.47) | KIF11ALDH1A3NOTUMALDH1A1ALDH3A1 | |
| SCHEMBL31335403 | 0.82 | XDH (0.44) | KIF11ALDH1A3NOTUMALDH1A1KDM4E | |
| SCHEMBL472408 | 0.81 | KIF11 (0.56) | KIF11ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL321346 | 0.80 | ALDH1A3 (0.47) | KIF11ALDH1A3ALDH1A1ALDH3A1KDM4E | |
| SCHEMBL6849159 | 0.79 | KIF11 (0.55) | KIF11ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL5408528 | 0.79 | PTPN1 (0.48) | — | |
| SCHEMBL6853514 | 0.78 | KIF11 (0.53) | KIF11ALDH1A3ALDH1A1KDM4EPTGS2 | |
| SCHEMBL48409 | 0.78 | KIF11 (0.73) | KIF11ALDH1A1KDM4EPTGS2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872844-A | Preparation method of 3-bromo-4- (trifluoromethyl) benzaldehyde | 上海筑裕新材料科技有限公司 | 2023-03-31 | — | — | CN | claimed |
| EP-4719605-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.4) Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4680608-A1 | 2,6-DIHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE DERIVATIVES AS ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2025-11-06 | — | — | US | disclosed |
| EP-3483142-B1 | AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING MAXINOVEL PHARMACEUTICALS CO LTD (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | ZYMEWORKS BC INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-09-25 | — | — | US | disclosed |
| EP-4605426-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-27 | — | — | EP | disclosed |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2025-07-24 | — | — | US | disclosed |
| EP-2910549-A1 | 1,2,3,4-TETRAHYDRO-1,1,4,4-TETRAMETHYLNAPHTHALENE DERIVATIVES USEFUL AS RXR MODULATORS FOR TREATING ALZHEIMER'S DISEASE AND CANCER | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| EP-2755942-A2 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013040227-A2 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013040227-A2 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2013-03-21 | — | — | WO | disclosed |
| US-6642222-B2 | Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions | ABBOTT LABORATORIES | 2003-11-04 | — | — | US | disclosed |
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| EP-1278747-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083484-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | KCNJ3, KCNJ6, KCNJ5 | KIF11 1859/4885ALDH1A3 1702/4885NOTUM 3349/4885 |
| US-20250339552-A1 | ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE | FOLR1, FOLR2, DHFR | KIF11 958/4885ALDH1A3 1772/4885NOTUM 4595/4885 |
| US-12433952-B2 | Antibody-drug conjugates targeting folate receptor alpha and methods of use | FOLR1, FOLR2, DHFR | KIF11 958/4885ALDH1A3 1772/4885NOTUM 4595/4885 |
| US-20250235548-A1 | ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USE | SLC34A2, SLC20A2, SLC34A1 | KIF11 1652/4885ALDH1A3 2025/4885NOTUM 3764/4885 |
| US-20250295799-A1 | ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE | B3GAT3, GALNT3, GOLGA3 | KIF11 1519/4885ALDH1A3 705/4885NOTUM 3342/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | KIF11 1914/4885ALDH1A3 1154/4885NOTUM 3318/4885 |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | MAPT, PSEN1, PSEN2 | KIF11 794/4885ALDH1A3 1753/4885NOTUM 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.